CoDx (CODX) - Long-Term Liabilities to Capital

PCR test sales volumes and Co-Primers licenses drive the current productivity of Co-Diagnostics, Inc. (CODX). Monitoring the long-term debt-to-equity ratio correlates with these processes, and the value of 0.08 reflects the latest debt load figure. The company achieves optimization through contract manufacturing and IT outsourcing. Co-Diagnostics, Inc. (CODX) is currently rebalancing its assets to create a universal digital platform for home virus diagnostics.

This metric compares liabilities with a maturity of over one year against equity, accounting for the market revaluation of assets. It determines the degree of financial autonomy and the risk of debt load. For Co-Diagnostics, Inc. (CODX), which is developing a high-precision molecular testing ecosystem, this serves as an indicator of the ability to scale technologies without excessive borrowing. The current value of 0.08 reflects the current balance of resources. Analyzing the long-term accounts payable to equity ratio allows for an assessment of the company's resilience to interest rate changes.